TITLE

Aortic Root Dilatation in Mucopolysaccharidosis I-VII

AUTHOR(S)
Bolourchi, Meena; Renella, Pierangelo; Wang, Raymond Y.
PUB. DATE
December 2016
SOURCE
International Journal of Molecular Sciences;Dec2016, Vol. 17 Issue 12, p2004
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The prevalence of aortic root dilatation (ARD) in mucopolysaccharidosis (MPS) is not well documented. We investigated aortic root measurements in 34 MPS patients at the Children's Hospital of Orange County (CHOC). The diagnosis, treatment status, age, gender, height, weight and aortic root parameters (aortic valve annulus (AVA), sinuses of Valsalva (SoV), and sinotubular junction (STJ)) were extracted by retrospective chart review and echocardiographic measurements. Descriptive statistics, ANOVA, and paired post-hoc t-tests were used to summarize the aortic dimensions. Exact binomial 95% confidence intervals (CIs) were constructed for ARD, defined as a z-score greater than 2 at the SoV. The patient age ranged from 3.4-25.9 years (mean 13.3 ± 6.1), the height from 0.87-1.62 meters (mean 1.24 ± 0.21), and the weight from 14.1-84.5 kg (mean 34.4 ± 18.0). The prevalence of dilation at the AVA was 41% (14/34; 95% CI: 25%-59%); at the SoV was 35% (12/34; 95% CI: 20%-54%); and at the STJ was 30% (9/30; 95% CI: 15%-49%). The highest prevalence of ARD was in MPS IVa (87.5%). There was no significant difference between mean z-scores of MPS patients who received treatment with hematopoietic stem cell transplantation (HSCT) or enzyme replacement therapy (ERT) vs. untreated MPS patients at the AVA (z = 1.9 ± 2.5 vs. z = 1.5 ± 2.4; p = 0.62), SoV (z = 1.2 ± 1.6 vs. z = 1.3 ± 2.2; p = 0.79), or STJ (z = 1.0 ± 1.8 vs. z = 1.2 ± 1.6; p = 0.83). The prevalence of ARD was 35% in our cohort of MPS I-VII patients. Thus, we recommend screening for ARD on a routine basis in this patient population.
ACCESSION #
120516827

 

Related Articles

  • Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure.  // Orphanet Journal of Rare Diseases;2011, Vol. 6 Issue 1, p55 

    The article presents a European consensus procedure which showed the use of enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) in the treatment of patient having mucopolysaccharidosis type I (MPS I). In this procedure a panel of specialists developed...

  • Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure.  // Current Medical Literature: Lysosomal Storage Disease;2012, Vol. 10 Issue 1, p28 

    The article focuses on the study regarding the use of hematopoietic stem cell transplantation and enzyme replacement therapy (ERT) for the diagnosis of mucopolysaccharidosis type (MPS I) I patients. It states that MPS IH can in early death, usually within the first 20 years of life, if left...

  • Mukopolysacharidóza I - klinické projevy u 24 dÄ•tí z ÄŒeské republiky a Slovenska. Ješina, P.; Magner, M.; Poupĕtová, H.; Honzíkova, J.; Dvořáková, L.; Malinová, V.; Hrubá, E.; Hlavatá, A.; Honzík, T.; Veselá, K.; Sedláček, P.; Starý, J.; Zeman, J. // Czecho-Slovak Pediatrics / Cesko-Slovenska Pediatrie;Jun2011, Vol. 66 Issue 4, p215 

    Mucopolysaccharidosis I (MPS I) is severe metabolic storage disease caused by impaired function of α-L-iduronidase. The aim of this study is to describe clinical symptoms, natural course and to evaluate results of treatment in Czech and Slovak children with MPS I. Methods: Study group...

  • Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years. Fernyhough, L J; Buchan, V A; McArthur, L T; Hock, B D // Bone Marrow Transplantation;Jan2013, Vol. 48 Issue 1, p32 

    There is an increasing trend towards long-term frozen storage of haematopoietic stem cells. For such stem cells, harvested from peripheral blood (PB) or BM, it is not known if stem cell viability decreases with time. In this study, 31 separate bags of stem cell product (SCP) stored for 11-19...

  • Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells. Tsukamoto, Hiroshi; Nagafuji, Koji; Horiuchi, Takahiko; Mitoma, Hiroki; Niiro, Hiroaki; Arinobu, Yojiro; Inoue, Yasushi; To, Kentaro; Miyamoto, Toshihiro; Iwasaki, Hiromi; Teshima, Takanori; Harada, Mine; Akashi, Koichi // Rheumatology;May2011, Vol. 50 Issue 5, p944 

    Objective. The aim of this study is to evaluate the mechanism of long-term effect of autologous haematopoietic stem cell transplantation (ASCT) in treatment of SSc.Methods. Eleven patients (three males and eight females) with SSc were enrolled. Blood mononuclear cells were harvested after...

  • Current and emerging treatments and surgical interventions for Morquio A syndrome: a review. Tomatsu, Shunji; Mackenzie, William G.; Theroux, Mary C.; Mason, Robert W.; Thacker, Mihir M.; Shaffer, Thomas H.; Monta�o, Adriana M.; Rowan, Daniel; Sly, William; Alm�ciga-D�az, Carlos J.; Barrera, Luis A.; Chinen, Yasutsugu; Yasuda, Eriko; Ruhnke, Kristen; Suzuki, Yasuyuki; Orii, Tadao // Research & Reports in Endocrine Disorders;2012 Part 2, p65 

    Patients with mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) have accumulation of the glycosaminoglycans, keratan sulfate, and chondroitin-6-sulfate, in bone and cartilage, causing systemic spondyloepiphyseal dysplasia. Features include lumbar gibbus, pectus carinatum, flaring of...

  • Hematopoietic Stem and Progenitor Cells Can Be Enriched by Implanting Biomaterial into Spatium Intermusculare. Tong, Jia-Bei; Wu, Xiao-Yun; Jia, Ge-Liuchang; Zhao, Kui-Jun; Wang, Shi-Li; Ma, Zhi-Jie // BioMed Research International;1/28/2015, Vol. 2015, p1 

    Hematopoietic stem and progenitor cells (HSPCs) have been used successfully to treat patients with cancer and disorders of the blood and immune systems. In this study, we tried to enrich HSPCs by implanting biomaterials into the spatium intermusculare of mice hind limbs. Gelatine sponges were...

  • Novel Therapies.  // Current Medical Literature: Lysosomal Storage Disease;2009, Vol. 8 Issue 3, p112 

    The article presents a study which reveals the outcome of haematopoietic stem cell transplantation (HSCT) in six children with mucopolysaccharidosis type IH. During the study, the children were assessed using a developmental before and after the application of HSCT. Researchers conclude that the...

  • Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantation. Polgreen, L. E.; Plog, M.; Schwender, J. D.; Tolar, J.; Thomas, W.; Orchard, P. J.; Miller, B. S.; Petryk, A. // Bone Marrow Transplantation;Sep2009, Vol. 44 Issue 5, p279 

    Children with Hurler syndrome experience progressive growth failure after hematopoietic cell transplantation (HCT). The goal of this study was to review the safety and efficacy of growth hormone (GH) in eight children with Hurler syndrome who were treated at our institution with GH for short...

  • Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Boelens, J. J.; Wynn, R. F.; O'Meara, A.; Veys, P.; Bertrand, Y.; Souillet, G.; Wraith, J. E.; Fischer, A.; Cavazzana-Calvo, M.; Sykora, K. W.; Sedlacek, P.; Rovelli, A.; Uiterwaal, C. S. P. M.; Wulffraat, N. // Bone Marrow Transplantation;Aug2007, Vol. 40 Issue 3, p225 

    Hurler's syndrome (HS), the most severe form of mucopolysaccharidosis type-I, causes progressive deterioration of the central nervous system and death in childhood. Allogeneic stem cell transplantation (SCT) before the age of 2 years halts disease progression. Graft failure limits the success of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics